GlassScriptPhysician profile
Hyeyoon Park
NPI 1760840201
$7,910.13
in general payments reported to CMS, 2019-2025
22 companies · $2,248 in 2025
The $2,248 reported for 2025 was more than what 95% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $981 · 2022: $811 · 2023: $1,314 · 2024: $2,556 · 2025: $2,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,859 · Education: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,859.43 |
| Education | $258.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,810.55 | 2021-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $1,318.77 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,100.76 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $752.97 | 2023-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $577.82 | 2021-2025 | Dupixent, Libtayo |
| Pfizer INC. | $498.91 | 2021-2025 | |
| Ucb, INC. | $385.79 | 2022-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $330.57 | 2022-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $292.43 | 2023-2024 | Vtama |
| Lilly USA, LLC | $181.69 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Organon LLC | $147.46 | 2024-2025 | Vtama |
| Amgen INC. | $94.88 | 2023-2025 | Otezla, Otezla |
| Genzyme Corporation | $78.95 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $77.15 | 2021-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $56.79 | 2023-2025 | Valchlor |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $44.11 | 2023-2024 | |
| Biofrontera INC. | $42.74 | 2021-2022 | |
| Incyte Corporation | $36.44 | 2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $32.26 | 2024 | Zoryve |
| Kyowa Kirin, INC. | $18.58 | 2024 | Poteligeo |
| Verrica Pharmaceuticals INC. | $16.16 | 2024 | Ycanth |
| Almirall LLC | $14.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hyeyoon Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.